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Tuberculosis (TB) and HIV care in Khayelitsha, and in South Africa as a whole, has overcome numerous obstacles 
in the past three decades. This article highlights what has been achieved in Khayelitsha, describes the key clinical 
programme and policy changes that have supported universal coverage for HIV and TB care over the last 10 years, 
and outlines the challenges for the next decade.
The evolution of tuberculosis (TB) and HIV care in 
Khayelitsha, and in Africa as a whole, has overcome 
numerous obstacles in the past three decades: poor 
leadership in acknowledging the HIV crisis, inadequate 
provision of appropriate scientific interventions, and 
scepticism about the feasibility of treatment programmes 
in settings challenged with extreme resource constraints. 
Over the past 10 years in Khayelitsha, HIV has been 
transformed from less than 500 people tested for HIV 
and no one on antiretroviral therapy (ART) in 1998 to 50 
000 tested and 20 000 on ART in 2011.1 Stakeholders in 
the Khayelitsha sub-district have reflected in the course 
of the past year on the previous decade of service 
developments as part of commemorating 10 years 
of public sector ART provision. This article highlights 
what has been achieved collectively by several service 
providers (the City of Cape Town, Médecins Sans 
Frontières, the Western Cape province, academic 
institutions, the Treatment Action Campaign (TAC), non-
governmental and community-based organisations), 
describes the key clinical programme and policy changes 
that have supported universal coverage for HIV and TB 
care over the past 10 years, and outlines the challenges 
for the next decade.
HIV PREVENTION AND INCIDENCE REDUCTION
Dedicated efforts have been made to scale up a 
combination of prevention interventions that has resulted 
in substantial changes in health outcomes over the past 
decade. 
PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV
The implementation of a prevention of mother-to-
child transmission (PMTCT) programme in 1999, with 
antenatal and perinatal antiretroviral chemoprophylaxis 
and free exclusive formula feeding, marked the beginning 
of public sector antiretroviral-based services in South 
Africa. This programme, with progressive improvements 
and intensification in line with the evolution of national 
guidelines, has resulted in a reduction in documented 
mother-to-child transmission from 12.5% in 2002 to 
2.5% in 2010 based on polymerase chain reaction (PCR) 
testing at 6 weeks (Fig. 1). This success is mirrored in 
many other sites in South Africa, and demonstrates that 
PMTCT to very low proportions of infants infected is both 
feasible and scalable. 
Fig. 1. Rate of mother-to-child HIV transmission, 2002 - 2010.
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Furthermore, the decentralisation of paediatric ART into 
primary care clinics, which started in 2004, resulted in a 
steady increase in children being initiated on ART each 
year, from 4 in 2001 to 145 in 2008. The numbers have 
decreased since then to 115 in 2010. The successful 
decentralisation of paediatric care has led to positive 
health outcomes; 87% of children started on ART in 
primary care remained in care, and 98% remained alive 
after 5 years on ART. 
HIV TESTING
HIV testing has increased steadily since the advent of the 
programme. The programme started with enzyme-linked 
immunosorbent assay (ELISA) testing of 500 people in 
January 1999. The introduction of rapid HIV testing kits, 
PCR testing for infants, employment of lay counsellors to 
conduct HIV counselling and testing (HCT), community-
based testing sites, wide-scale HCT campaigns, and 
targeted testing for TB patients/suspects, youth and 
males saw a dramatic increase in the numbers of people 
being tested each year. By the end of 2010, 22 centres 
were providing HCT and approximately 57 000 people 
were being tested annually. In a community survey 
conducted in 2004, 28% of men and 53% of women of 
reproductive age in Khayelitsha reported having been 
tested for HIV.2 
COMMUNITY CONDOM DISTRIBUTION
Male condom distribution has been a major priority in 
the programme. The number of condoms distributed per 
year increased from 2 million in 2004 to more than 10 
million in 2006; currently more than a million condoms 
are distributed every month. This was made possible 
through the combined efforts of the public sector, 
including the City of Cape Town, and non-governmental 
organisations, especially TAC. TAC expanded condom 
distribution from health care facilities to community 
distribution points, such as taxi ranks, public libraries, 
toilets and shebeens.3 During the same period, the 
number of adults reported to have been treated for 
sexually transmitted infections (STIs) decreased 
fourfold, from 28 000 in 2004 to less than 5 000 in 2009. 
OPENING OF A MALE-FRIENDLY CLINIC
Recognition of the need for a service dedicated to 
reaching men and providing HCT and STI treatment 
resulted in the opening of a male walk-in clinic at a taxi 
rank in 2007. This new service was widely advertised 
in the community through the use of taxi ranks and 
the local radio. This clinic has become the largest STI 
treatment site in the Cape Metro area, with the number 
of STIs treated increasing from 843 in 2007 to 2 547 
in 2010. In the first half of 2011 the clinic counselled 
and tested as many men as were tested throughout 
2010, and the number tested during 2010 in the male 
clinic represented 27% of all men tested in Khayelitsha. 
The clinic aims to promote and empower men to take 
ownership of their sexual health and safety and that of 
their partners. Its success demonstrates that men use 
health services that are adapted to their needs: short 
waiting times, close to a usual gathering place for men 
(taxi rank), and separate from public health services 
attended mostly by women and children. Two new male 
clinics are planned for 2011 to continue to reach out to 
men, who remain a group with limited access to care. 
ANTIRETROVIRAL THERAPY
In May 2011 there were 20 000 patients on ART, which 
is estimated to represent 63% coverage of those in 
need in Khayelitsha, according to current World Health 
Organization (WHO) eligibility criteria. Retention in 
care at one year on ART has remained consistently 
above 85% since the beginning of the programme.4 
In addition, virological suppression among patients in 
care also remained above 87% in those tested,4 thereby 
decreasing the community viral load given the relatively 
high proportion of infected adults who are on ART. It is 
therefore likely that this is contributing to a reduction in 
the number of new HIV infections. 
EVOLUTION OF HIV PREVALENCE
HIV prevalence among women presenting for antenatal 
care has been routinely measured by the programme 
since 1999, and since 2003 the testing acceptance rate 
has been close to 100%. The antenatal HIV prevalence 
among those who test in routine care has stabilised since 
2006 and may now be declining (Fig. 2). This decline is 
not mirrored by the annual anonymous antenatal survey, 
which might be explained by the fact that in routine care 
Box 1. Key elements of the programme 
Khayelitsha is a large township with approximately 
500 000 inhabitants, located on the outskirts of Cape 
Town. It has one of the highest burdens of both HIV 
and toberculosis (TB) in South Africa. An estimated 
16% of the population is HIV infected; TB incidence is 
above 1 500/100 000 per year and TB/HIV co-infection 
is close to 70%. The incidence of drug-resistant TB is 
estimated at 50/100 000 per year.11
The Khayelitsha programme, started in 1999, was the 
first in South Africa to provide antiretroviral therapy 
(ART) at primary care level in the public sector and 
one of two pilot projects in the country to provide 
decentralised care for drug-resistant tuberculosis.12 
Key strategies implemented include:
■prevention of mother to child transmission with ART 
and formula 
■large-scale HIV counselling and testing, including 
out-of-facility testing, youth clinics,and male clinics
■mass community condom distribution
■decentralisation of ART to all clinics in the sub-
district
■ ‘one-stop-shop’ integration of ART and TB services
■nurse management of HIV and TB care, including 
nurse-initiated ART and TB treatment
■doctor support and mentorship, with a strong 
secondary care referral system
■district level planning and co-ordination
■three-tier monitoring and evaluation system (paper 
register, electronic register,and electronic medical 
record in selected sites)
■ongoing training and mentoring at clinic and district level
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women already on ART are often not retested for HIV, 
whereas during the annual survey all pregnant women 
are tested, regardless of whether they are on ART or 
not. Considering the decreased mortality, the absence 
of an increase in antenatal prevalence in recent years 
could be the result of the benefits of ART offsetting 
reduced new infections. 
Emerging data illustrate that treatment serves as a 
powerful prevention tool,5 and to decrease HIV incidence 
there is a need to combine wide-scale access to ART 
with available prevention tools, including HCT, PMTCT 
and condom distribution. In parallel, there is the need to 
focus on innovative tools to measure HIV incidence in 
order to adequately assess HIV prevention efforts. 
DECREASING MORBIDITY
Increasing access to ART, as a result of decentralisation, 
task shifting and TB/HIV integration, has allowed 
patients to access and initiate treatment earlier. This 
in turn has resulted in decreasing HIV-related mortality 
and morbidity. Patients presenting to care earlier are 
also typically less complex to manage clinically, which 
facilitates increased nurse management of care. 
EVIDENCE OF EARLIER ART ACCESS
Median CD4 counts of people starting ART increased 
from 43 cells/µl in 2001 to 162 cells/µl in 2010. In the 
same period the proportion of patients presenting with a 
WHO stage IV diagnosis decreased from 50% to 20%. 
BETTER ART REGIMENS
The programme has also seen a gradual evolution 
towards improved first-line regimens. Documentation of 
high rates of adverse events with the use of stavudine 
(d4T) contributed to the growing evidence base that 
led to the WHO recommendation to replace d4T with 
better-tolerated alternatives.6 A tenofovir-based regimen 
was introduced in 2005 in Khayelitsha for patients 
experiencing d4T toxicity, and was included in the 
national first-line regimen for all patients in 2010.
INTEGRATION OF TB AND HIV SERVICES
The ‘one-stop-shop’ integration of TB and HIV services 
began in 2004, and allowed co-infected patients to 
access TB and HIV services in the same clinic and from 
the same health staff.7 In 2010, 99% of TB patients in 
TB/HIV integrated clinics were offered HCT, and 95% of 
them were being tested. Furthermore, 99% of co-infected 
patients had a CD4 count result recorded and over 95% 
were started on co-trimoxazole preventive therapy. 
The successful integration of the services has led to 
improvements in the detection rates of smear-negative 
pulmonary TB and extrapulmonary TB, as nurses’ 
clinical skills in managing both diseases improved. In 
addition, integration has resulted in a decrease in the 
median time from the start of TB treatment to ART 
initiation.7 Improved TB diagnostic methods, including 
smear-negative algorithms, systematic TB culture, line-
probe assays, and the piloting of GeneXpert, as well as 
the systematic screening of HIV patients for TB, are all 
expected to contribute to increased TB diagnosis. The 
integration of HIV/TB care has been accompanied by 
improved TB cure rates (from 44% in 2005 to 81% in 
2010), despite the increased caseload. 
COMMUNITY-BASED MANAGEMENT OF DRUG-RESISTANT TB
Before 2007, all patients with drug-resistant tuberculosis 
(DR-TB) in Khayelitsha had to be admitted to a central TB 
hospital to receive their treatment. Khayelitsha has piloted 
a community-based DR-TB programme in which drug- 
resistant TB is diagnosed and treated in primary care 
clinics as opposed to a centralised facility. The number of 
cases of DR-TB diagnosed increased from 14 in 2003 to 
200 in 2010. Over 80% of patients diagnosed with DR-TB 
in 2009 and 2010 started treatment. The decentralisation 
of care was able to ensure that 71% of cases started 
treatment through the local clinic, while only 14% were 
admitted to the centralised specialist DR-TB hospital. In 
addition, the median time to treatment initiation decreased 
from 71 days in 2007 to 33 days in 2010. 
DECREASING MORTALITY
DECENTRALISED, TB/HIV INTEGRATED, NURSE-MANAGED ART
Recorded mortality of adults at 3 months on ART 
decreased from 10% in 2002 to 2.2% in 2010, in part 
due to patients accessing ART earlier. While mortality 
ascertainment is less complete in recent years, there 
remains a year-on-year decline in mortality even after 
linkage to the national death registry to correct for 
mortality under-ascertainment.4 Recorded mortality 
of adults at one year on ART decreased from under 
15% to 8% between 2002 and 2007.4 This decline in 
Box 2. Community-based model of care for drug-
resistant tuberculosis
■Drug-resistant tuberculosis (DR-TB) refers to TB 
that has become resistant to first-line treatment and 
requires longer and more difficult treatment with 
second-line anti-TB drugs.
■Instead of attempting to hospitalise all DR-TB 
patients, the Khayelitsha model of care uses a 
patient-centred approach with community-based 
treatment through existing primary care services.
■Using lessons learned from the decentralisation 
of HIV care, diagnosis and treatment of DR-TB 
has been integrated into the routine TB and HIV 
programmes in Khayelitsha since early 2008.
Fig. 2. Khayelitsha antenatal prevalence, 1999 - 2010.CHC = 
community health centre; City Clinic = City of Cape Town Clinic.
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early mortality and earlier access to ART has occurred 
alongside a dramatic increase from 100 people initiated 
on ART in 2001 to approximately 20 000 by mid-2011 
(Fig. 3). The sharp rise in treatment enrolment was made 
possible due to decentralisation of ART to every clinic, 
TB/HIV integration, and nurse-managed ART and TB 
care. Decentralised care began in 2006 and new clinics 
were accredited as ART sites each year thereafter. 
National guidelines allowed for nurse-initiated TB/
HIV integrated ART in April 2010, and all 11 clinics in 
Khayelitsha were providing ART by the end of 2010. In 
terms of longer-term outcomes, previous data based on 
death registry linkage have also confirmed that 4 out of 
5 patients who started treatment were alive 5 years after 
starting treatment.4
PATIENTS TREATED FOR DRUG-RESISTANT TUBERCULOSIS
While there has been an increase in the detection 
of DR-TB, the Khayelitsha programme has seen an 
improvement in the survival of people with DR-TB. Of 
those diagnosed with DR-TB in 2008, 62.4% remained 
alive after 18 months, reflecting an overall mortality of 
38%. While mortality levels remain high, given that 76% 
of all DR-TB patients are HIV infected, this represents 
significant improvements in health outcomes among 
people with DR-TB compared with other settings.8 
CHALLENGES
RETENTION IN CARE
While the programme has achieved many successes, 
several challenges remain in ensuring universal access 
to ART. With the advent of improved drug regimens and 
models of care, HIV has become a manageable chronic 
disease. Approximately 85% of patients are retained in 
care after 12 months, while only 65% of patients are still 
in care at 5 years on treatment; this highlights the need 
for further innovations to improve long-term retention. 
With increased enrolment came increased losses to 
follow-up, probably due to saturation of services, patient 
mobility and death. This trend in patient losses to follow-
up stabilised and even began to decrease in the later 
years as a result of the adoption of measures to adapt 
to the high numbers of patients on treatment. Innovative 
models of care included the introduction of adherence 
clubs and nurse management of patients. 
MEN
The proportion of men among adults starting ART 
remains lower than expected. Although the male walk-
in clinic has driven an increase in men testing for HIV 
and seeking treatment for STIs, men still represent only 
30% of adults in care after 10 years of ART treatment 
in Khayelitsha. There is a need to develop programmes 
that cater to men’s needs in order to improve their 
access to health services. Furthermore, given that men 
rarely accompany their partners to antenatal services, 
innovative mechanisms will be required to identify 
serodiscordant couples in light of emerging guidelines 
that will recommend the use of ART to reduce the risk of 
HIV transmission to the negative partner.5
YOUTH
Pre-ART loss to follow up is particularly high among 
youth. In 2010, up to 70% of eligible young people in the 
youth clinics were lost to care before starting ART; 60% 
of these losses occurred immediately after HIV testing. 
Youth on ART were also more likely than older adults to 
be lost to follow-up.9 Recognition of the need to focus 
specific interventions targeted at this high-risk group 
led to the establishment in 2005 of two youth clinics 
that provide adapted and targeted services. Although 
pre-ART loss to follow-up declined in 2010 – from 70% 
and 60% in the first quarter to 45% and 29% in the last 
quarter for the two youth clinics, respectively – early 
loss to care remains high and is indicative of the need to 
continue to adapt services and interventions that cater 
appropriately to the needs of youth. 
TREATMENT FAILURE
At 5 years on ART, approximately 14% of patients had 
confirmed virological failure and 12% were on second-
line ART.4 Mortality and treatment failure are found to be 
high in patients on second-line treatment. Out of the 32% 
of patients who failed second-line ART, 60% had poor 
adherence, and 30% returned to undetectable viral loads 
after enhanced adherence support; the remainder were 
switched to a third-line regimen. This highlights the need 
for early detection of poor adherence in order to provide 
targeted enhanced adherence support. A recent study 
in Khayelitsha demonstrated that a viral load performed 
at 3 months resulted in better virological outcomes 
than one performed at 6 months,10 demonstrating the 
usefulness of the viral load for early detection of poor 
adherence and virological failure. Third-line drugs are 
currently not available in the public sector due to their 
high costs. As access to and time on ART increases, 
the number of patients requiring second- and third-line 
regimens is rising, and prices for these drugs will need 
to be driven down. 
THE FUTURE  
The key clinical challenges for the next decade will be to 
achieve universal coverage of patients in need of ART, 
retain patients in care, and decrease the number of 
new infections. This will necessitate innovative models 
of care to decrease the burden of patients on chronic 
treatment on health facilities – thereby allowing the 
facilities to increase enrolment on ART – and improve 
long-term adherence and retention, as well as the 
implementation of combination prevention strategies.
Fig. 3. Monthly patient ART enrollment, 2001 - 2010.
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ADHERENCE CLUBS
Adherence clubs were established to improve clinic 
efficiency (decongest clinics and allow clinicians time 
for initiating patients), sustain high enrolment targets, 
and improve long-term adherence. The adherence clubs 
are group clinic visits for stable patients that are run by 
lay health workers and meet every 2 months. On club 
days patients receive their medication and are screened 
for opportunistic infections and adverse events, and are 
referred to a clinician if necessary. In addition, patients 
receive an educational talk on the day of their visit. 
By the end of 2010, a total of 30 clubs were created, 23 
of them situated in the community and 7 in the Ubuntu 
Clinic in Khayelitsha. More than 750 people were 
enrolled in total. An early evaluation revealed that after 
1 year of enrolment in the clubs, 99.2% of the patients 
were alive; at 2 years this figure stood at 97.5%. After the 
first year of enrolment, loss to follow-up was 1.1% and 
mortality 0.7%. This model is currently being expanded 
to other clinics in order to increase coverage. With 
the adoption of new national regulations, community 
health care workers will now be able to manage these 
clubs effectively. There is still a need to adapt the drug 
distribution system further in order to allow for regulated 
and quality-assured chronic drug dispensing units that 
are able to provide medications more conveniently to 
patients in the community, thereby ensuring that there is 
increased access to treatment closer to patient’s homes. 
REDUCING HIV AND TB INCIDENCE
Despite some early positive signs, the national target of 
a 50% reduction in HIV incidence is not close to being 
achieved. An exception to this is in the area of PMTCT, 
where transmission has been reduced by 80% since the 
beginning of the programme. There is a need to continue 
to focus on sustained behavioural interventions, 
including widespread condom distribution, out-of-facility 
community-based testing, and biomedical interventions 
to reduce HIV incidence. New targeted pre-exposure 
prophylaxis strategies (particularly for women wishing 
to have children), initiation of ART at a CD4 count of 
500 cells/µl, new drug formulations and technologies 
including fixed-dose combinations, point-of-care viral 
load and CD4 testing, and robust low-toxicity regimens 
must be explored. 
Furthermore, there is a need to continue to focus on the 
early diagnosis and treatment of TB and DR-TB, both 
to improve individual patient outcomes and to reduce 
transmission. Despite dramatic improvements in case 
detection for DR-TB, only half of all estimated DR-TB 
cases are diagnosed in Khayelitsha, and there is a need to 
increase case detection to curb HIV transmission. Access 
to molecular diagnostics, including GeneXpert, shows 
promising results in increasing detection of TB and DR-TB. 
This could also provide a sensitive screening tool for the 
provision of INH prophylaxis in TB-negative patients. 
DISCUSSION
The success in scaling up HIV/TB service provision 
in Khayelitsha is attributed to the collaborative efforts 
of service providers, policy makers, academics, civil 
society and the community at large. The Khayelitsha 
programme was successful in achieving community 
buy-in because it offered a reliable service within the 
community, was supported through partnerships, and 
was complemented by widespread treatment literacy. 
While the district is best known for its role in demonstrating 
the feasibility of ART in resource-constrained settings, 
some of the most important lessons have come in 
more recent years, where the latent capacity of South 
Africa’s public health system has been demonstrated 
when subjected to energy, innovation and meaningful 
collaboration. In spite of the numerous partnerships, 
Khayelitsha remains a difficult environment in which to 
deliver services, but it has nevertheless been possible 
to achieve coverage and scale for a number of activities 
beyond the most optimistic outlooks of a decade ago. 
In the areas of PMTCT and ART provision this is 
being demonstrated in South Africa as a whole, where 
expectations have been exceeded in recent years.
Increased funding for antiretrovirals and the resulting 
increase in access to care helped to strengthen the 
Box 3. Strategies for the future – innovation and 
wide implementation
■Further out-of-facility community-based testing (in 
schools, taxi ranks, community halls) 
■Initiation of antiretroviral therapy at higher CD4 
thresholds, potentially up to CD4s of 500 cells/µl 
and/or high viral load thresholds, to further reduce 
viral circulation and infectiousness at community 
level (treatment as prevention, TASP)
■Community-based delivery of ART by community 
health workers and/or chronic dispensing units
■Increased investment in pre-ART (e.g. by creating 
pre-ART adherence clubs)  
■New pre-exposure prophylaxis strategies targeting 
young female adolescents combined with development 
of new long-acting antiretroviral formulations and 
other biomedical preventive interventions.
These strategies will have to be supported by new 
drug formulations and technologies, including:
■fixed-dose combinations for first- and second-line 
regimens
■semi-quantitative point of care viral load dipstick 
to monitor adherence and identify early treatment 
failures  
■POC CD4 devices to reduce pre-ART loss to follow-
up, mostly among adolescents 
■more robust regimens with a better safety profile, 
including drugs like darunavir, which maintains a 
low toxicity in the long term once the viral load has 
become undetectable
■ensure appropriate access to reproductive health 
services, including Pap smears for all women 
including those living with HIV and medical 
termination of pregnancy at the primary health level.
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overall health system, and the implementation of a 
large-scale TB/HIV programme resulted in decreased 
rates of both illness and death among people living 
with HIV as well as a likely reduction in the number 
of new HIV infections. This unique clinical programme 
contributed to national policy changes that have had a 
tangible impact on the lives of thousands of people living 
with HIV and TB in South Africa, and has demonstrated 
the possibility of achieving universal coverage of ART 
and positive patient outcomes in resource constrained 
settings.
Challenges ahead include the need to reduce HIV 
transmission in the community. The Khayelitsha 
programme has paved the way for innovative approaches 
to treatment provision that have allowed an increasing 
number of people to access quality treatment closer to 
their communities. The future of HIV and TB treatment 
and care will require a focus on combination prevention 
and treatment interventions, in addition to the adoption 
of new innovations that can have a tangible impact on 
the spread of the dual epidemics. 
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